Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Nature Medicine2016Vol. 22(3), pp. 262–269
Citations Over TimeTop 1% of 2016 papers
Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, María Gomez‐Caraballo, Faria M. Siddiqui, Hillary E. Mulvey, Yosef E. Maruvka, Fei Ji, Hyo-Eun Carrie Bhang, Viveksagar Krishnamurthy Radhakrishna, Giulia Siravegna, Haichuan Hu, Sana Raoof, Elizabeth L. Lockerman, Anuj Kalsy, Dana Lee, Celina L Keating, David A. Ruddy, Leah J. Damon, Adam Crystal, Carlotta Costa, Zofia Piotrowska, Alberto Bardelli, A. John Iafrate, Ruslan I. Sadreyev, Frank Stegmeier, Gad Getz, Lecia V. Sequist, Anthony C. Faber, Jeffrey A. Engelman
Related Papers
- → Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy(2017)8 cited
- → Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report(2014)5 cited
- → 9017 POSTER DISCUSSION Initial Detection of the Double Epidermal Growth Factor Receptor (EGFR) Mutation (L858R or Deletion in Exon 19 [del 19] Plus T790M) in Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Brain Metastases (mets) and the Influence of First-Line Chemotherapy on Outcome to Erlotinib(2011)
- → 21 High sensitivity detection of epidermal growth factor receptor (EGFR) T790M mutants in non-small-cell lung cancer(2013)
- → Detection of epidermal growth factor receptor-T790M mutation in circulating tumor DNA of lung cancer patients for tyrosine kinase inhibitor acquired resistance(2018)